Literature DB >> 27416787

Role of routine computed tomography scan in the oncological follow up of patients treated by radical cystectomy for bladder cancer.

Quentin Alimi1, Grégory Verhoest1, Solene-Florence Kammerer-Jacquet2, Romain Mathieu1, Nathalie Rioux-Leclercq2, Andréa Manunta1, Brigitte Laguerre3, François Guille1, Karim Bensalah1, Benoit Peyronnet4.   

Abstract

OBJECTIVES: To assess the impact of a prolonged follow-up schedule using computed tomography scan on oncological outcomes after radical cystectomy for bladder cancer.
METHODS: A single-center retrospective study was carried out. All patients who underwent a radical cystectomy for bladder cancer between 1992 and 2012 were included. The protocol for postoperative oncological follow up included a thoracoabdominal computed tomography scan twice per year for 2 years and then annually for life. The patients with tumor recurrence were divided into two groups: asymptomatic recurrences and recurrences diagnosed because of symptoms. Cancer-specific survivals were estimated using the Kaplan-Meier method and compared with the log-rank test. Cox proportional hazards regression models were used to determine the predictive factors of cancer-specific survival.
RESULTS: Overall, 331 patients were included in this analysis, and, of them, 48.5% had a cancer recurrence after a median follow up of 52.6 months. A total of 30 of these recurrences were diagnosed at routine follow up among asymptomatic patients (18.8%). A total of 50% of recurrences occurred during the first 6 months and 75% during the first year. Just 10 of the recurrences (6.3%) appeared more than 3 years after radical cystectomy. The 5-year cancer-specific survival was higher in patients with asymptomatic recurrences (15.7% vs 32.1%), but this difference was not statistically significant (P = 0.10). On multivariate analysis, detection of asymptomatic recurrence reached statistical significance (HR 0.55; P = 0.04).
CONCLUSION: Routine computed tomography scan surveillance after radical cystectomy for bladder cancer might provide a survival benefit. The risk of recurrence beyond 3 years seems to be low, and further studies are required to determine the role of routine computed tomography scan in the follow up beyond this timeframe.
© 2016 The Japanese Urological Association.

Entities:  

Keywords:  bladder cancer; follow up; recurrence; survival; tomography

Mesh:

Year:  2016        PMID: 27416787     DOI: 10.1111/iju.13164

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  5 in total

1.  Association Between Symptomatic Versus Asymptomatic Recurrence and Survival in Bladder Cancer.

Authors:  Chelsea K Osterman; Jaber Alanzi; James D Lewis; Elizabeth L Kaufman; Vivek Narayan; Ben Boursi; Ravy K Vajravelu; Frank I Scott; S Bruce Malkowicz; Ronac Mamtani
Journal:  Clin Genitourin Cancer       Date:  2017-12-06       Impact factor: 2.872

2.  [Follow-up surveillance of muscle-invasive urinary bladder cancer after curative treatment].

Authors:  G B Schulz; C G Stief; B Schlenker
Journal:  Urologe A       Date:  2019-09       Impact factor: 0.639

3.  Detecting asymptomatic recurrence after radical nephroureterectomy contributes to better prognosis in patients with upper urinary tract urothelial carcinoma.

Authors:  Hirotaka Horiguchi; Shingo Hatakeyama; Go Anan; Yuka Kubota; Hirotake Kodama; Masaki Momota; Koichi Kido; Hayato Yamamoto; Yuki Tobisawa; Tohru Yoneyama; Takahiro Yoneyama; Yasuhiro Hashimoto; Takuya Koie; Hiroyuki Ito; Kazuaki Yoshikawa; Toshiaki Kawaguchi; Makoto Sato; Chikara Ohyama
Journal:  Oncotarget       Date:  2018-01-04

4.  Risk-stratified surveillance protocol improves cost-effectiveness after radical nephroureterectomy in patients with upper tract urothelial carcinoma.

Authors:  Masaki Momota; Shingo Hatakeyama; Hayato Yamamoto; Hiromichi Iwamura; Yuki Tobisawa; Tohru Yoneyama; Takahiro Yoneyama; Yasuhiro Hashimoto; Takuya Koie; Ikuya Iwabuchi; Masaru Ogasawara; Toshiaki Kawaguchi; Chikara Ohyama
Journal:  Oncotarget       Date:  2018-05-01

Review 5.  Asymptomatic recurrence detection and cost-effectiveness in urothelial carcinoma.

Authors:  Hiromichi Iwamura; Shingo Hatakeyama; Makoto Sato; Chikara Ohyama
Journal:  Med Oncol       Date:  2018-05-09       Impact factor: 3.064

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.